(Boursier.com) — Nicox SA, an international company specializing in ophthalmology, today announces the signing of an exclusive licensing agreement with Kowa Company Ltd, for the development and marketing in Japan of NCX 470, a nitric oxide donor bimatoprost eye drops from Nicox , for the reduction of intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.
Kowa, a global Japanese pharmaceutical company, is engaged in innovative research, development and marketing activities.
“We are very pleased that Kowa will become our exclusive partner for our main asset, NCX 470, for the Japanese market. This commitment from a player of this stature in the field of ophthalmology confirms the scientific and marketing of the NCX 470, particularly for Japanese patients.” said Emmet Purtill, Vice President of Business Development at Nicox. “Japan represents one of the largest markets for ophthalmic therapeutic products. Therefore, this collaboration significantly strengthens the global sales potential of the NCX 470 whose annual global net sales have been estimated at $300 million by the Society.”
©2024 Boursier.com